Preclinical evidence and mechanistic insights of ligustilide in ischemic stroke: a systematic review and meta-analysis
Präklinische Evidenz und mechanistische Erkenntnisse zu Ligustilid beim ischämischen Schlaganfall: systematische Übersicht und Metaanalyse
Frontiers in Pharmacology · 21.11.2025 · 16
DOI: 10.3389/fphar.2025.1666207 ↗Auf einen Blick
In 13 präklinischen Studien verringerte Ligustilid in Tiermodellen des ischämischen Schlaganfalls das Infarktvolumen und verbesserte neurologische Scores.
Fragestellung
Welche präklinische Evidenz gibt es für die Wirksamkeit von Ligustilid in Tiermodellen des ischämischen Schlaganfalls?
Methode
Systematische Suche in PubMed, Web of Science und Embase nach präklinischen Studien; Metaanalyse zu Infarktvolumen und neurologischer Funktion.
Ergebnisse
13 Studien. Ligustilid reduzierte das Infarktvolumen (SMD 3,26; 95 %-KI 2,31–4,22) und verbesserte neurologische Scores (SMD 1,64; 95 %-KI 1,13–2,15).
Einschränkungen
Heterogenität möglicherweise durch Unterschiede in Modellierung, Applikationsweg und Mehrfachdosen bedingt.
Schlussfolgerung der Autor:innen
Die Übersichtsarbeit liefert präklinische Evidenz für protektive Effekte von Ligustilid in Tiermodellen des ischämischen Schlaganfalls über mehrere Zielmechanismen.
Kernaussagen
- Infarktvolumen unter Ligustilid geringer
- Neurologische Scores verbessert
- Oxidativer Stress und Entzündung vermindert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.11.2025. Verfasst von Hengtong An und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Integrated Traditional Chinese and Western Medicine, Hebei University of Chinese Medicine, Hebei, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Ligustilide, a phthalide-derived bioactive compound abundantly found in traditional Chinese medicinal herbs such as Angelica sinensis (Danggui) and Ligusticum chuanxiong (Chuanxiong), has attracted increasing attention for its potential therapeutic benefits in ischemic stroke (IS). However, its clinical applications remain limited, and the comprehensive preclinical evidence regarding its efficacy and mechanisms of action is still unclear. Materials and methods A systematic search of PubMed, Web of Science, and Embase was conducted to identify preclinical studies evaluating the effects of Ligustilide in IS animal models. A meta-analysis was performed to quantitatively assess the efficacy of Ligustilide in reducing infarct volume and improving neurological function. Additional analyses explored its potential mechanisms and the sources of heterogeneity.
Results
The pooled results from 13 studies demonstrated that Ligustilide significantly reduced infarct volume (SMD = 3.26, 95% CI [2.31, 4.22], P < 0.05) and improved neurological scores (SMD = 1.64, 95% CI [1.13, 2.15], P < 0.05) in animal models of IS compared to control groups. Mechanistically, Ligustilide exerted protective effects by alleviating oxidative stress [lowering Malondialdehyde (MDA) levels (n = 3) and enhancing Superoxide Dismutase (SOD) (n = 2) and Glutathione (GSH) (n = 2) levels], suppressing inflammatory responses [reducing Tumor Necrosis Factor-alpha (TNF-α) (n = 3)], and a non-significant trend toward reduced apoptosis was also noted based on TUNEL staining (n = 2, P = 0.054), warranting further investigation. Sensitivity analyses confirmed the robustness of the findings. Subgroup analyses indicated that heterogeneity might be associated with differences in modeling methods, administration routes, and the use of multiple intervention doses.
Conclusion
This systematic review and meta-analysis provides comprehensive preclinical evidence supporting the protective effects of Ligustilide in IS animal models through multi-target mechanisms. Future large-scale, high-quality animal studies and clinical trials are needed to further validate its therapeutic potential and facilitate its translational application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Integrated Traditional Chinese and Western Medicine, Hebei University of Chinese Medicine, Hebei, China.
- Science and Technology Achievement Transformation Center, Hebei University of Chinese Medicine, Hebei, China.
- Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Hebei University of Chinese Medicine, Hebei, China.
Zitieren
APA
An, H., Guo, S., Wang, W., Zheng, T., Jin, X., Zhou, X., & Gao, W. (2025). Preclinical evidence and mechanistic insights of ligustilide in ischemic stroke: a systematic review and meta-analysis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1666207
Vancouver
An H, Guo S, Wang W, Zheng T, Jin X, Zhou X, et al. Preclinical evidence and mechanistic insights of ligustilide in ischemic stroke: a systematic review and meta-analysis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1666207
BibTeX
@article{An2025,
author = {An, Hengtong and Guo, Shuhan and Wang, Wei and Zheng, Tiangang and Jin, Xiaofei and Zhou, Xiaohong and Gao, Weijuan},
title = {Preclinical evidence and mechanistic insights of ligustilide in ischemic stroke: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1666207}
}
EUVIMED